A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

BACKGROUND: Src is involved in cancer invasion and metastasis. AZD0424, an oral inhibitor of Src and ABL1, has shown evidence of anti-tumour activity in pre-clinical studies. METHODS: A phase Ia, dose escalation study was performed to assess the safety of continuous oral dosing with AZD0424 in advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodcock, Victoria K, Clive, Sally, Wilson, Richard H, Coyle, Vicky M, Stratford, Michael R L, Folkes, Lisa K, Eastell, Richard, Barton, Claire, Jones, Paul, Kazmi-Stokes, Shamim, Turner, Helen, Halford, Sarah, Harris, Adrian L, Middleton, Mark R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877436/
https://www.ncbi.nlm.nih.gov/pubmed/29438361
http://dx.doi.org/10.1038/bjc.2017.484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877436/
https://www.ncbi.nlm.nih.gov/pubmed/29438361
http://dx.doi.org/10.1038/bjc.2017.484

Ejemplares similares